EUVIMEDEUVIMED entdecken
Crossref

High‐Performance Liquid Chromatography–Ultraviolet Assay for the Determination of Pirtobrutinib Levels in a Patient With Mantle Cell Lymphoma

Yoshito Gando iD, Takeo Yasu iD, Mari Shimoda, Masao Tukada

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Yoshito Gando und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Ja…. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Pyrimidines, Pyrazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pirtobrutinib is a Bruton's tyrosine kinase inhibitor used to treat mantle cell lymphoma and chronic lymphocytic leukemia. Pirtobrutinib has a steady‐state trough concentration of > 825 ng/mL, corresponding to a 90% inhibitory concentration of Bruton's tyrosine kinase. Therefore, maintaining stable trough concentrations of pirtobrutinib is clinically important; however, no methods of monitoring pirtobrutinib levels have been developed. In this study, our aim was to develop a method to determine pirtobrutinib levels in human plasma and validate it for therapeutic drug monitoring. Pirtobrutinib and ibrutinib (internal standard) were separated on a reversed‐phase column using a mobile phase comprising 0.5% KH 2 PO 4 (pH 4.5) and acetonitrile (52:48, v/v) at a flow rate of 1.0 mL/min. Ultraviolet detection was performed at 234 nm. Calibration curves for pirtobrutinib were linear ( r 2 = 0.9998) in the range of 0.25–10 μg/mL. The intraday and interday validation coefficients were 0.72%–2.86% and 1.29%–3.22%, respectively. This study is the first one to develop and validate a method for quantifying pirtobrutinib in human plasma. These findings may support the widespread application of therapeutic drug monitoring for pirtobrutinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellPyrimidinesPyrazolesHumansChromatography, High Pressure LiquidLinear ModelsReproducibility of ResultsLimit of DetectionPiperidinesDrug MonitoringAdenineAntineoplastic Agents

Stichwörter der Autor:innen

Bruton's tyrosine kinase inhibitorhigh‐performance liquid chromatography–ultraviolethuman plasma concentrationmantle cell lymphomapirtobrutinib

Substanzen

PyrimidinesPiperidinesAdeninePyrazolesAntineoplastic Agentspirtobrutinib

Autor:innen und Institutionen

  • Department of Medicinal Therapy Research, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Tokyo, Japan.
  • Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
  • Department of Hematology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.

ORCID-Profile: Yoshito Gando, Takeo Yasu

Förderung

  • Nagai Memorial Research Scholarship from the Pharmaceutical Society of Japan

Zitieren

APA

Gando, Y., Yasu, T., Shimoda, M., & Tukada, M. (2025). High‐Performance Liquid Chromatography–Ultraviolet Assay for the Determination of Pirtobrutinib Levels in a Patient With Mantle Cell Lymphoma. Biomedical Chromatography. https://doi.org/10.1002/bmc.70061

Vancouver

Gando Y, Yasu T, Shimoda M, Tukada M. High‐Performance Liquid Chromatography–Ultraviolet Assay for the Determination of Pirtobrutinib Levels in a Patient With Mantle Cell Lymphoma. Biomedical Chromatography. 2025. doi:10.1002/bmc.70061

BibTeX
@article{Gando2025,
  author = {Gando, Yoshito and Yasu, Takeo and Shimoda, Mari and Tukada, Masao},
  title = {High‐Performance Liquid Chromatography–Ultraviolet Assay for the Determination of Pirtobrutinib Levels in a Patient With Mantle Cell Lymphoma},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70061}
}
Kostenlos starten →